医药生物行业动态点评：重症医学政策出台，助推市场扩容

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The introduction of policies to enhance critical care services is expected to expand the market for high-end medical equipment, including ventilators and ECMO devices. The government aims to increase the number of ICU beds to 15 per 100,000 people by the end of 2025 and to 18 by the end of 2027, which will significantly boost the critical care market [3]. - The critical care market in China is projected to reach USD 1.637 billion by 2027, with a CAGR of 7.41% from 2021 to 2027, driven by the new policies [3]. - Companies such as Mindray Medical and Lifetech Scientific are recommended for investment due to their involvement in critical care equipment [3]. Summary by Sections Policy Impact - The Chinese government has issued a directive to improve critical care services, which includes increasing the number of ICU beds and enhancing the capabilities of medical institutions [3]. - The policy encourages the introduction of advanced treatment technologies and aims to fill the gaps in critical care expertise [3]. Market Projections - The critical care market is expected to grow significantly, with specific targets set for ICU bed availability by 2025 and 2027 [3]. - The anticipated market size by 2027 is USD 1.637 billion, indicating a robust growth trajectory [3]. Investment Recommendations - The report suggests focusing on companies involved in critical care equipment, particularly Mindray Medical and Lifetech Scientific, as they are well-positioned to benefit from the expanding market [3].